The tirzepatide molecule: what makes it different from other weight-loss medicines

The biggest myth: tirzepatide is just a stronger version of a GLP-1 medicine

A common assumption is that tirzepatide works the same way as semaglutide or liraglutide, just at a higher dose. That's not quite right. Older GLP-1 medicines target one receptor. Tirzepatide was engineered to activate two: the GLP-1 receptor and the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is a hormone released in the small intestine after eating. It plays a role in insulin secretion, fat storage, and, crucially, appetite signalling in the brain.

Designing a molecule that fits both receptors credibly required rebuilding the peptide backbone. Tirzepatide starts from a 39-amino-acid sequence modelled on natural GIP, then incorporates a fatty-acid chain that binds to albumin in the bloodstream. That albumin binding slows clearance from the body, extending the molecule's half-life to roughly five days, which is what makes once-weekly dosing possible. A pure copy of natural GIP would be broken down within minutes.

The result is a molecule that influences appetite, gastric emptying, and blood-sugar regulation through two complementary mechanisms at once. Whether you're curious about the chemistry or want to understand the structural detail, the key practical point is this: dual-receptor activation is a genuinely different mechanism, not a dose adjustment of something older.

The full tirzepatide overview covers how these mechanisms connect to its licensed use in the UK.

What the molecule actually does once it's injected

After a subcutaneous injection, tirzepatide binds to GLP-1 receptors in the gut and brain, reducing appetite and slowing the rate at which the stomach empties into the small intestine. Meals feel satisfying with less food, and the urge to eat again arrives later. That part is shared with GLP-1-only medicines.

The GIP-receptor arm adds a second layer. GIP receptors sit in the brain's reward and appetite centres, and activating them appears to reduce the hedonic pull of food, the wanting it even when you're not hungry. Research suggests GIP receptor activity also influences how fat tissue responds to insulin, which may contribute to metabolic improvements beyond weight alone. The picture at the cellular level is still being mapped, and if you'd like a closer look at the published data on its molecular formula and receptor-binding properties, that detail is covered separately.

In the SURMOUNT-1 trial, published in the New England Journal of Medicine, participants using tirzepatide at the highest dose saw an average body-weight reduction of around 20–21% over 72 weeks alongside diet and activity changes. NICE reviewed this evidence before recommending tirzepatide in December 2024, NICE Technology Appraisal TA1026 sets out the full recommendation and eligibility criteria. The Mounjaro page explains how that recommendation connects to private prescribing.

Why the molecule's size and structure affect how you take it

Tirzepatide is a large peptide. Peptides of this size are broken down by digestive enzymes before they can reach the bloodstream, which is why tirzepatide cannot be taken as an ordinary tablet, injection delivers it directly into subcutaneous tissue, bypassing the gut entirely. That's a practical consequence of the molecule's biology, not a limitation of the formulation.

The molecular weight of tirzepatide sits at roughly 4,813 daltons, which sits firmly in the large-peptide category. Its fatty-acid modification, mentioned earlier, lets it travel in the bloodstream attached to albumin rather than floating free, stabilising it and sustaining its action across a full week between doses.

Storage follows from this too: the molecule is sensitive to heat, which is why pens are kept refrigerated at 2–8°C. How long a pen can sit at room temperature before use is something the Patient Information Leaflet covers precisely, a question our prescribers hear most weeks, so it's worth checking yours rather than relying on a general figure. The NHS tirzepatide medicines page is a reliable first reference for storage and practical handling questions.

If you'd like to explore the structural chemistry further, the tirzepatide-L page covers specific structural variants and their significance.

Who can access tirzepatide in the UK, and via which route

Tirzepatide is licensed in the UK as Mounjaro, sold in KwikPens, each containing four weekly doses. The licence covers weight management in adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related condition such as raised blood pressure, high cholesterol, or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, the NICE appraisal specifies a 2.5 kg/m² adjustment for South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

NHS access is being phased in gradually and currently reaches people with a BMI of 40 or above and four or more of a defined list of weight-related conditions. For those who don't meet NHS criteria, or who'd rather not wait, a private prescription from a regulated online pharmacy is the alternative. Pricing context (what a private course typically costs and what that includes) is covered on our weight-loss treatments overview.

Treatment starts at 2.5mg, a tolerability dose whose job is settling the body to the medicine before doses increase. The schedule is managed by the prescriber, not self-directed. If this sounds relevant to your situation, checking your eligibility with our clinical team is the straightforward next step, consultations are free, and a GPhC-registered prescriber reads every one the same day.